Table of Contents Author Guidelines Submit a Manuscript
Advances in Urology
Volume 2014, Article ID 746298, 6 pages
http://dx.doi.org/10.1155/2014/746298
Research Article

Neoadjuvant Chemotherapy Use in Bladder Cancer: A Survey of Current Practice and Opinions

1Department of Urology, Oregon Health and Science University, 3303 SW Bond Avenue, Portland, OR 97239, USA
2Department of Public Health and Preventive Medicine, Oregon Health and Science University, 3303 SW Bond Avenue, Portland, OR 97239, USA
3Department of Urology, University of Wisconsin, Madison, WI 53705, USA
4MSKCC, Department of Surgery, Urology Service, New York, NY 10065, USA
5National Cancer Institute, Medical Oncology Branch and Affiliates, Bethesda, MD 20892, USA
6Department of Urology, University of Washington, Seattle, WA 98195, USA

Received 10 February 2014; Accepted 10 May 2014; Published 28 May 2014

Academic Editor: Douglas S. Scherr

Copyright © 2014 N. G. Cowan et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. November 2012, http://www.cancer.gov/cancertopics/types/bladder.
  2. November 2012, http://www.cancer.org/cancer/bladdercancer/detailedguide/bladder-cancer-survival-rates.
  3. H. B. Grossman, R. B. Natale, C. M. Tangen et al., “Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer,” The New England Journal of Medicine, vol. 349, no. 9, pp. 859–866, 2003. View at Publisher · View at Google Scholar · View at Scopus
  4. C. L. Vale, “Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data,” European Urology, vol. 48, no. 2, pp. 202–205, 2005. View at Publisher · View at Google Scholar · View at Scopus
  5. G. Griffiths, “International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial,” Journal of Clinical Oncology, vol. 29, no. 16, pp. 2171–2177, 2011. View at Publisher · View at Google Scholar · View at Scopus
  6. A. Stenzl, N. C. Cowan, M. De Santis et al., “Treatment of muscle-invasive and metastatic bladder cancer: update of EAU guidelines,” European Urology, vol. 59, pp. 1009–1018, 2011. View at Google Scholar
  7. K. A. David, M. I. Milowsky, J. Ritchey, P. R. Carroll, and D. M. Nanus, “Low incidence of perioperative chemotherapy for stage III bladder cancer 1998 to 2003: a report from the National Cancer Data Base,” Journal of Urology, vol. 178, no. 2, pp. 451–454, 2007. View at Publisher · View at Google Scholar · View at Scopus
  8. G. V. Raj, S. Karavadia, B. Schlomer et al., “Contemporary use of perioperative cisplatin-based chemotherapy in patients with muscle-invasive bladder cancer,” Cancer, vol. 117, no. 2, pp. 276–282, 2011. View at Publisher · View at Google Scholar · View at Scopus
  9. J. J. Meeks, J. Bellmunt, B. H. Bochner et al., “A systematic review of neoadjuvant and adjuvant chemotherapy for muscle-invasive bladder cancer,” European Urology, vol. 62, no. 3, pp. 523–533, 2012. View at Publisher · View at Google Scholar · View at Scopus
  10. M. Burger, P. Mulders, and W. Witjes, “Use of neoadjuvant chemotherapy for muscle-invasive bladder cancer is low among major European centres: results of a feasibility questionnaire,” European Urology, vol. 61, no. 5, pp. 1070–1071, 2012. View at Publisher · View at Google Scholar · View at Scopus
  11. U. Fedeli, S. A. Fedewa, and E. M. Ward, “Treatment of muscle invasive bladder cancer: evidence from the national cancer database, 2003 to 2007,” Journal of Urology, vol. 185, no. 1, pp. 72–78, 2011. View at Publisher · View at Google Scholar · View at Scopus
  12. H. W. Herr, Z. Dotan, S. M. Donat, and D. F. Bajorin, “Defining optimal therapy for muscle invasive bladder cancer,” Journal of Urology, vol. 177, no. 2, pp. 437–443, 2007. View at Publisher · View at Google Scholar · View at Scopus
  13. G. Niegisch, A. Lorch, M. J. Droller, H. J. Lavery, K. D. Stensland, and P. Albers, “Neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer: which patients benefit?” European Urology, vol. 64, no. 3, pp. 355–357, 2013. View at Publisher · View at Google Scholar · View at Scopus
  14. S. M. Donat, “Integrating perioperative chemotherapy into the treatment of muscle-invasive bladder cancer: strategy versus reality,” Journal of the National Comprehensive Cancer Network, vol. 7, no. 1, pp. 40–43, 2009. View at Google Scholar · View at Scopus
  15. International Collaboration of Trialists, “Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trial,” The Lancet, vol. 354, pp. 533–540, 1999. View at Google Scholar
  16. C. T. Lee, R. Madii, S. Daignault et al., “Cystectomy delay more than 3 months from initial bladder cancer diagnosis results in decreased disease specific and overall survival,” Journal of Urology, vol. 175, pp. 1262–1267, 2006. View at Google Scholar
  17. S. S. Chang, J. M. Hassan, M. S. Cookson, N. Wells, and J. A. Smith Jr., “Delaying radical cystectomy for muscle invasive bladder cancer results in worse pathological stage,” Journal of Urology, vol. 170, no. 4, part 1, pp. 1085–1087, 2003. View at Publisher · View at Google Scholar · View at Scopus
  18. A. S. Alva, C. T. Tallman, C. He et al., “Efficient delivery of radical cystectomy after neoadjuvant chemotherapy for muscle-invasive bladder cancer: a multidisciplinary approach,” Cancer, vol. 118, no. 1, pp. 44–53, 2012. View at Publisher · View at Google Scholar · View at Scopus
  19. C. N. Sternberg, J. Bellmunt, G. Sonpavde et al., “ICUD-EAU international consultation on bladder cancer 2012: chemotherapy for urothelial carcinoma—neoadjuvant and adjuvant settings,” European Urology, vol. 63, no. 1, pp. 58–66, 2013. View at Publisher · View at Google Scholar · View at Scopus
  20. A. Dash, M. D. Galsky, A. J. Vickers et al., “Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder,” Cancer, vol. 107, no. 3, pp. 506–513, 2006. View at Publisher · View at Google Scholar · View at Scopus
  21. A. Eldefrawy, M. S. Soloway, D. Katkoori, R. Singal, D. Pan, and M. Manoharan, “Neoadjuvant and adjuvant chemotherapy for muscle-invasive bladder cancer: the likelihood of initiation and completion,” Indian Journal of Urology, vol. 28, no. 4, pp. 424–426, 2012. View at Publisher · View at Google Scholar · View at Scopus